Scarless Laboratories Announces Positive Results from its Phase 1/2a Clinical Study in Scar Reduction

　　
Los Angeles, California–Scarless Laboratories, Inc., a biotechnology company with a platform technology in scar reduction and wound healing, announced today that it has completed its First-in-Human Phase 1/2a clinical study for improvement in scar appearance and wound healing in patients undergoing elective abdominoplasty.

Scarless’ platform technology is based on its lead candidate SLI-F06, a novel peptide that had previously demonstrated safety and preliminary effectiveness in large animal models, has now been shown to be safe in humans and to improve the appearance of acute scars in patients undergoing elective abdominoplasty when compared to vehicle control.

In a 22-patient clinical study conducted at 3 Investigative sites in the United States, SLI-F06 treated study arm showed significant improvement in scar appearance when compared to vehicle (placebo). With proof of concept and safety complete Scarless’ clinical plans include further study including dose optimization in abdominoplasty and in scar revision and treatment of Diabetic Foot Ulcers.“

Completion of our first Phase 1/2a clinical study is a major milestone for Scarless” said Dr. Soo “and we look forward to continued development and expansion with our SLI-F06 platform technology to help the millions of people who are burdened with untreated or inadequately treated scars and wounds.”

The economic and physiological burden of scaring is staggering. There are an estimated 12 million traumatic lacerations treated in the U.S. emergency rooms each year, 250 million surgical incisions created worldwide every year, and 11 million burns severe enough to warrant medical treatment worldwide.  In the U.S alone, over $20 billion per year are spent on the treatment and management of scars.  Scars can be associated with severe psychological, physical, and functional complications that erode an individual’s quality of life. Currently  there are no approved drugs or biologics that can adequately address the existing unmet need for effective therapies in the multi-billion-dollar scar and wound healing markets.
 

About Scarless Laboratories, Inc.

Scarless Laboratories is a clinical stage biotechnology company focused on revolutionizing tissue repair and disrupting the billion-dollar scar prevention, scar reduction, and chronic wound healing industries. Scarless was founded by UCLA Professors Drs. Chia Soo, Ting Kang and Zheng Zhong  and is located in Los Angeles, California. It is supported by private investors and National Institute of Health (NIH) grants.

For more information, please visit www.scarlessLabs.com.